Furthermore, a lower level of PD-L1 expression and tumor mutation burden (TMB) in KRAS G12D has also emerged in a more recent study (PD-L1 tumor proportion score KRAS G12D vs. non G-12D: 1% vs. 5%, p < 0.01; TMB G12D vs. non-G12D: median 8.4 versus 9.9 mt/Mb, p < 0.0001) [106]. Here, KRAS is linked to neoplasm.